Alimera Sciences Price/Book
What is the Price/Book of Alimera Sciences?
The Price/Book of Alimera Sciences Inc. is 0.36
What is the definition of Price/Book?
Price to book ratio represents the ratio between a company’s stock value and the book value per share.
mrq (most recent quarter)
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Price/Book of companies in the Health Care sector on NASDAQ compared to Alimera Sciences
What does Alimera Sciences do?
alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.
Companies with price/book similar to Alimera Sciences
- NWS has Price/Book of 0.36
- Koenig & Bauer AG has Price/Book of 0.36
- Best Pacific International has Price/Book of 0.36
- Bambuser AB (publ) has Price/Book of 0.36
- Gravity (India) has Price/Book of 0.36
- Gemdale Properties and Investment has Price/Book of 0.36
- Alimera Sciences has Price/Book of 0.36
- Tritax EuroBox plc has Price/Book of 0.36
- Vasta Platform has Price/Book of 0.36
- EyePoint Pharmaceuticals Inc has Price/Book of 0.36
- Valeura has Price/Book of 0.36
- Devernois S.A has Price/Book of 0.36
- Inozyme Pharma has Price/Book of 0.37